Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Equity Income (2022 - 2023)

Silo Pharma's Equity Income history spans 2 years, with the latest figure at -$3508.0 for Q2 2023.

  • For Q2 2023, Equity Income rose 94.11% year-over-year to -$3508.0; the TTM value through Dec 2023 reached -$98092.0, changed N/A, while the annual FY2023 figure was -$3118.0, 99.06% up from the prior year.
  • Equity Income for Q2 2023 was -$3508.0 at Silo Pharma, up from -$35073.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$3508.0 in Q2 2023 and bottomed at -$59511.0 in Q2 2022.